Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II TrialJ. Clin. Oncol 2018 Aug 14;[EPub Ahead of Print], M Rimawi, JM Ferrero, J de la Haba-Rodriguez, C Poole, S De Placido, CK Osborne, R Hegg, V Easton, C Wohlfarth, G Arpino
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.